会议现场图片(来源:X平台) AACR Annual Meeting 2024在X社交平台上共有6,290位参与者,推送了26,313个帖子,产生超过5.53亿次阅读。The Innovation本年度主要由医学及肿瘤相关X平台账号参与会议内容推广,共发推/转推约2,000次,推动超过3.12亿次阅读,占本次大会X平台阅读总量的56%,并且重点关注了中国学者和中国企业...
announces its participation at the 2024 American Association for Cancer Research (AACR) Annual Meeting on April 5-10, San Diego, where it will present results of preclinical studies of TSN1611(Poster# 3315), a pot...
2024年美国癌症研究协会年会 (AACR ANNUAL MEETING 2024)于当地时间4月5日-10日在美国圣地亚哥召开。在本次会议上,映恩生物以壁报形式公布基于其自主研发的抗肿瘤ADC平台DITAC (Duality Immune Toxin Antibody Conjugate)开发的DB-1310、DB-1311创新项目的研究成果,信息如下: 壁报信息1 Title: A Phase 1/2a, multic...
We're excited to announce that ICE Bioscience will be participating in the AACR Annual Meeting 2024 from April 5-10 at the San Diego Convention Center. You can find us at booth#4228, where we'll be ready to dive into discussions about our state-of-the-art oncology services. Our dedicated...
The 115th American Association for Cancer Research (AACR) Annual Meeting was held in San Diego, USA, April 5-10, 2024. The AACR Annual Meeting, as one of the leading cancer conferences in the world, has always been a focus of attention in the global pharmaceutical industry. The themeof ...
(serplulimab) as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) was published as poster presentation at the American Association for Cancer Research 2024 meeting (AACR 2024), with Professor Ying Cheng from Jilin Province Cancer Hospital as the leading ...
(ADC) developed in partnership with LigaChem Biosciences (LCB), formerly LegoChem Biosciences, (KOSDAQ: 141080), at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The poster presentation highlights LNBC74's promising preclinical safety and anti-tumor ...
2024年4月10日,复宏汉霖(2696.HK)宣布,公司首个创新型单抗H药 汉斯状(斯鲁利单抗)一线治疗广泛期小细胞肺癌(ES-SCLC)的国际多中心III期临床试验ASTRUM-005的探索性生物标志物分析数据在2024年美国癌症协会年会(AACR 2024)上以壁报形式展示,该研究的主要研究者为吉林省肿瘤医院程颖教授。
2024年4月10日,复宏汉霖(2696.HK)宣布,公司首个创新型单抗H药 汉斯状®(斯鲁利单抗)一线治疗广泛期小细胞肺癌(ES-SCLC)的国际多中心III期临床试验ASTRUM-005的探索性生物标志物分析数据在2024年美国癌症协会年会(AACR 2024)上以壁报形式展示,该研究的主要研究者为吉林省肿瘤医院程颖教授。
(SMARCA2) selective inhibitor will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 in San Diego, California. In addition to the FHD-909 poster, the Company will have a symposium presentation, a town hall talk, and poster ...